RB1 and neoplasm: On the other hand, the onco‐suppressor pRb (RB1), the main target of CDK4, has been found to be intact in most MPMs, pointing out these tumours as paradigmatic targets for CDK4/6 inhibitors (CDK4/6i) [8, 12].